• Home

  • About Us

    • Overview

    • Culture

    • Team

  • Drug R & D

    • Fields

    • Indications

    • Pipeline

  • Technology Platform

    • Biotechnology Platform

    • Chemistry Service

  • News Center

    • Company News

    • Industry News

  • Join Us

    • Team Building

    • Career Development

  • Contact Us

CN
EN
We Expect You To Join Us!

We Expect You To Join Us!

——

Join Us

图片名称

Team Building

Career Development

Join Us

Team Building

Career Development

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models


previous page

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor induces targeted-protein degradation through lysosomal autophagy

BB5523, a multiple kinase inhibitor with HPK1, VEGFR2 and TNIK inhibition, enhanced antitumor immunity in tumor models

next page

上一页

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor induces targeted-protein degradation through lysosomal autophagy

next page

BB5523, a multiple kinase inhibitor with HPK1, VEGFR2 and TNIK inhibition, enhanced antitumor immunity in tumor models

address:

A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176

phone:

010-58222729

e-mail:

hr@broadenbio.com

 

Copyright ©2019 BroadenBio

SEO

Powered by www.300.cn

business license